Tech Company Financing Transactions
Adimab Funding Round
On 4/2/2012, Adimab announced Series F funding from private investors.
Transaction Overview
Company Name
Announced On
4/2/2012
Transaction Type
Venture Equity
Amount
Unknown
Round
Series F
Investors
Proceeds Purpose
We are accelerating the expansion of our platform to include additional applications such as the development of bi-specific antibodies, antibody-drug conjugates, targeting cell based antigens including GPCRs and ion channels, as well as preclinical manufacturing and mammalian cell line development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7 Lucent Dr.
Lebanon, NH 03766
USA
Lebanon, NH 03766
USA
Phone
Website
Email Address
Overview
Adimab is an antibody discovery and optimization platform, developing full-length human Immunoglobulin Gs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tillman Gerngross
Chief Financial Officer
Ryan McGovern
Chief Scientific Officer
Eric Krauland
Co-Founder
Dane Wittrup
VP - Bus. Development
Guy Meter
VP - General Counsel
Philip Chase
Browse more venture capital transactions:
Prev: 4/2/2012: Emerald Therapeutics venture capital transaction
Next: 4/2/2012: Good Start Genetics venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on funding rounds that are announced publicly. VC transactions reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs